Results 1 to 10 of about 1,193,284 (249)
Antiphospholipid Antibodies and Systemic Scleroderma
Turkish Journal of Hematology, 2013 Objective: Antiphospholipid antibodies (APLs) could be associated with an increased risk of vascular pathologies in systemic scleroderma. The aim of our study was to search for APLs in patients affected by systemic scleroderma and to evaluate their ...
Awa Oumar Touré +8 more
doaj +8 more sources
Systemic Scleroderma-Definition, Clinical Picture and Laboratory Diagnostics. [PDF]
J Clin Med, 2022 (1) Background: Scleroderma (Sc) is a rare connective tissue disease classified as an autoimmune disorder. The pathogenesis of this disease is not fully understood. (2) Methods: This article reviews the literature on systemic scleroderma (SSc).
Kowalska-Kępczyńska A.
europepmc +2 more sources
Prevalence of Oral and Maxillofacial Disorders in Patients with Systemic Scleroderma-A Systematic Review. [PDF]
Int J Environ Res Public Health, 2021 Background: Systematic scleroderma is a rare chronic autoimmune disease of unknown aetiology. The aim of this study was to identify the prevalence of orofacial pathognomonic conditions in patients with systemic scleroderma using only randomised ...
Benz K +5 more
europepmc +2 more sources
Pathophysiology of systemic sclerosis (scleroderma)
The Kaohsiung Journal of Medical Sciences, 2022 AbstractSystemic sclerosis (scleroderma) is an autoimmune‐triggered chronic fibrosing disease that affects the skin and many other organs. Its pathophysiology is complex and involves an early endothelial damage, an inflammatory infiltrate and a resulting fibrotic reaction.
Ann‐Helen Rosendahl +2 more
openaire +4 more sources
Oxidative stress in the pathogenesis of systemic scleroderma: An overview. [PDF]
J Cell Mol Med, 2018 Systemic sclerosis (SSc) is a rare disorder of the connective tissue characterized by fibrosis of the skin, skeletal muscles and visceral organs. Additional manifestations include activation of the immune system and vascular injury. SSc causes disability
Vona R +5 more
europepmc +2 more sources
Systemic sclerosis sine scleroderma [PDF]
Advances in Clinical and Experimental Medicine, 2017 Systemic sclerosis is a rare generalized disease with scleroderma, i.e. skin thickening as one of the most common symptoms. The disease has 2 main subsets, diffuse and limited forms. The subset known as systemic sclerosis sine scleroderma (ssSSc) is a very rare subset characterized by the total or partial absence of cutaneous manifestations of systemic
Magdalena Kopeć-Mędrek +1 more
openaire +4 more sources
Uncommon skeletal findings in systemic sclerosis (scleroderma)
South African Journal of Radiology, 2002 Scleroderma or progressive systemic sclerosis is a diffuse disease characterised by excessive deposition of collagen and small-vessel arteritis. Systemic sclerosis is divided into two groups. 1.
Betsie van der Walt +2 more
doaj +3 more sources
Frontiers in Immunology, 2019 Systemic sclerosis is a profibrotic autoimmune disease mediated by the dysregulation of extracellular matrix synthesis. Formyl peptide receptor 2 (Fpr2) is a G protein-coupled receptor that modulates inflammation and host defense by regulating the ...
Gyu Tae Park, Tae Wook Lee
exaly +3 more sources
Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features [PDF]
Arthritis Research & Therapy, 2011 IntroductionIn the present study, we analysed in detail nuclear autoantibodies and their associations in systemic sclerosis (SSc) patients included in the German Network for Systemic Scleroderma Registry.MethodsSera of 863 patients were analysed ...
Rudolf Mierau +24 more
openalex +2 more sources
Epithelial Fli1 deficiency drives systemic autoimmunity and fibrosis: Possible roles in scleroderma
Journal of Experimental Medicine, 2017 Systemic sclerosis (SSc), or scleroderma, is a multisystem autoimmune disorder characterized by vasculopathy and fibrosis in the skin and internal organs, most frequently in the esophagus and lungs.
Takehiro Takahashi +14 more
openalex +2 more sources